A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi) in Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primary Biliary Cirrhosis
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Maralixibat (Primary) ; Ursodeoxycholic acid
- Indications Primary biliary cirrhosis
- Focus Therapeutic Use
- Acronyms CLARITY
- Sponsors Lumena Pharmaceuticals; Mirum Pharmaceuticals
- 17 Apr 2016 Primary endpoint has not been met. (Change from baseline in pruritus compared to placebo), as per an abstract presented at The International Liver Congress™ 2016.
- 17 Apr 2016 Results presented at The International Liver Congress 2016
- 09 Apr 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.